^
    Back
    Association details:
    Biomarker:IGH mutation
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Zydelig (idelalisib) (PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Lancet Oncol
    Title:

    Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

    Excerpt:
    Randomisation was stratified by high-risk features (IGHV, del[17p], or TP53 mutation)...Idelalisib in combination with bendamustine plus rituximab improved progression-free survival compared with bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukaemia.
    Secondary therapy:
    bendamustine
    DOI:
    10.1016/S1470-2045(16)30671-4
    Trial ID:
    Tugela